Compare American Tower Corp (AMT) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs AstraZeneca plc — how do they compare? American Tower Corp trades at $169.8 (market cap $78.54B), while AstraZeneca plc trades at $169.73 (market cap $262.75B). The key difference: AstraZeneca plc is far larger — about 3.3× American Tower Corp's market cap, and American Tower Corp pays the higher dividend (4.14%). Which is the better fit depends on your goals.
| AMT | AZN | |
|---|---|---|
Market Cap | $78.54B | $262.75B |
Sector | Real Estate | Health |
52-Week High | $232.35 | $209.48 |
52-Week Low | $162.11 | $137.44 |
Enterprise Value | $122.07B | $289.00B |
Dividend Yield | 4.14% | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower (AMT) trades at $168.59, up 2.18% today, with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals including a 26.81% net margin and 82.19% ROE. Recent news highlights its data center growth and sustainability initiatives, while analyst consensus remains strongly bullish with a $214.10 price target.
AMT presents a compelling long-term investment opportunity given its high profitability, dividend yield, and market leadership, though elevated debt levels and near-term technical weakness pose risks. Upside potential exists if the company continues executing on 5G and data center expansion, but investors should monitor interest rate sensitivity and competitive pressures.
AstraZeneca (AZN) trades at $171.61, down 3.85% following a Phase 3 clinical trial failure for its Wainua heart drug. The stock faces bearish technical signals with support at $167 and resistance at $177. Fundamentally, the company maintains strong profitability with 17.19% net margins and robust revenue growth, reaching $58.74B in 2025. Analyst consensus remains positive with 47.5% buy ratings despite recent setbacks.
The outlook remains cautiously optimistic as AstraZeneca's core business fundamentals remain intact with improving cash flow and debt reduction. However, pipeline execution risks and clinical trial uncertainties present near-term headwinds. Long-term investors may find value at current levels given the company's strong market position and financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
